期刊
ONCOGENE
卷 34, 期 43, 页码 5411-5417出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2015.5
关键词
-
资金
- American Society of Clinical Oncology Young Investigator Award
- NIH K12 grant
- NIH R01 grant [1-R01 CA1633793-01]
- Cancer Prevention Institute of Texas [RP120108]
- Prostate Cancer Foundation Challenge Grant in Immunology
- American Association for Cancer Research/Cancer Research Institute/Stand-Up-To-Cancer Dream Team grant
Targeting a T-cell inhibitory checkpoint with the anti-CTLA-4 monoclonal antibody, ipilimumab, represents a scientific breakthrough in immunotherapy for the treatment of cancer. However, ipilimumab therapy is also associated with unique side effects, known as immune-related adverse events (irAEs), which need to be recognized and managed with immunosuppressive agents. To date, the majority of our knowledge regarding ipilimumab-associated side effects is based upon clinical studies in melanoma. Here we provide a review of ipilimumab-induced irAEs and our experience in a cohort of 44 patients with prostate cancer who were treated at the MD Anderson Cancer Center on two different clinical trial protocols.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据